Filing Details
Inmune Bio, Inc. (NASDAQ:INMB) filed a Form 8-K with the Securities and Exchange Commission on July 01, 2026, disclosing a material event.
8k filedNASDAQ:INMB
Inmune Bio, Inc. (INMB) Reports Material Event to SEC
Filing Details Inmune Bio, Inc. (NASDAQ:INMB) filed a Form 8-K with the Securities and Exchange Commission on July 01, 2026, disclosing a material event. Market Context Inmune…
Market Context
Inmune Bio, Inc.'s stock currently trades at $1.68 with a market capitalization of $56.6M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Inmune Bio, Inc.'s stock.
All SEC filings for Inmune Bio, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View INMB Stock Page
Frequently Asked Questions
Where can I read INMB's SEC filings?
Browse all filings on our INMB SEC filings page.
What types of SEC filings does Inmune Bio, Inc. file?
Public companies like Inmune Bio, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.